Rilpivirine-其他小分子化合物-深圳欣博盛生物科技有限公司

首页产品中心其他小分子化合物

Rilpivirine

品牌：Adipogen

官网链接

说明书

折扣/货期

货号：AG-CR1-3750-M005	规格：5 mg	目录价：￥600
货号：AG-CR1-3750-M025	规格：25 mg	目录价：￥2400
货号：AG-CR1-3750-M100	规格：100 mg	目录价：￥5160

产品详情

* 以下信息仅供参考，详情请以原厂网站为准

产品名称:

Rilpivirine

别名:

R278474; TMC278; DB08864

产品描述:

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC50 value of 0.51nM. It is active against NNRTI-resistant HIV strains with EC50 values less than 1nM for L100I, K103N, V106A, G190A and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC50s = <10nM), including strains containing up to eight resistance mutations. NNRTIs work by binding to and blocking HIV reverse transcriptase, which prevents HIV from replicating and lowers the amount of HIV in the blood. Rilpivirine is an antiviral anti-HIV drug, active against wild-type and NNRTI-resistant HIV-1 with higher potency, longer half-life and reduced side-effect profile compared with Efavirenz (Prod. No. AG-CR1-3751). CARD8 inflammasome senses HIV-1 protease activity. In HIV1-infected cells, CARD8 cannot detect the virus because the viral protease remains inactive as a subunit of unprocessed Gag-Pol polyprotein. HIV-1-specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), such us Rilpivirine, can trigger CARD8 sensing because they bind to HIV-1 Pol and enhance intracellular Gag-Pol polyprotein dimerization, which causes premature viral protease activation. Treating HIV-1-infected macrophages and CD4+ T cells with NNRTIs leads to CARD8-mediated caspase-1 activation and pyroptotic cell death. Induction of the CARD8 inflammasome activation has led to rapid clearance of latent HIV-1 in patient CD4+ T cells after virus reactivation.

保存温度:

+4°C

运输温度:

Ambient

预期分子量:

366.4

产品形式:

solid

产地:

瑞士

纯度:

>98% (HPLC)